Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure
Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'Keefe SJD, Forbes A, Heinze H, +1 more
Gastroenterology (2012) · n=86
63% of teduglutide-treated short-bowel-syndrome patients achieved 20–100% reduction in weekly parenteral-support volume versus 30% on placebo at 24 weeks — the pivotal Phase 3 result behind FDA approval and the closest precedent the GI-peptide field has for a peptide carrying a registration-quality program to a marketed indication.
This is the STEPS Phase 3 trial behind the FDA's December 2012 approval of teduglutide (Gattex in the United States, Revestive in Europe) as the first peptide therapy for adult short bowel syndrome with intestinal failure. Teduglutide is a recombinant 33-amino-acid glucagon-like peptide-2 analog engineered with a single Ala-to-Gly substitution at position 2 to resist degradation by dipeptidyl peptidase-4 — a stabilization strategy parallel to the one that produced the long-acting GLP-1 analogs but applied to the structurally distinct GLP-2 hormone and its intestinotrophic biology on crypt-cell proliferation, villous height, and mucosal-surface-area expansion.
The trial enrolled 86 adults with short bowel syndrome and intestinal failure requiring at least three days per week of parenteral support to maintain hydration and nutrition, with stable parenteral-support requirements documented across an optimization period. Patients were randomized 1:1 to once-daily subcutaneous teduglutide at 0.05 mg/kg/day (n = 43) or placebo (n = 43) for 24 weeks, conducted across 27 centers in North America and Europe. The primary endpoint was the proportion of patients achieving a 20–100% reduction in weekly parenteral-support volume from baseline through weeks 20 and 24, sustained across that two-visit confirmation window. Secondary endpoints captured absolute reduction in parenteral-support volume, achievement of at least one full day per week off parenteral support, and ileostomy-output and stool-volume reductions in subgroups.
The primary endpoint was met: 27 of 43 patients (63%) on teduglutide achieved the response criterion versus 13 of 43 (30%) on placebo (p = 0.002). Mean reduction in parenteral-support volume at week 24 was 4.4 ± 3.8 L/wk on teduglutide versus 2.3 ± 2.7 L/wk on placebo (p < 0.001). Twenty-one of 39 teduglutide patients (54%) achieved at least one additional day per week off parenteral support, with thirteen patients (33%) achieving two or more days off — a quality-of-life-relevant secondary signal that translated through the regulatory dossier. The adverse-event profile was dominated by injection-site reactions, gastrointestinal symptoms (abdominal pain, nausea), and the GLP-2-class biology-derived signals on stomal complications and gastrointestinal-tract neoplasia surveillance flags. The long-term extension is captured in the STEPS-2 publication; the pediatric Phase 3 followed in Kocoshis et al. 2020.
Within the IBD-and-peptides dossier context, the STEPS Phase 3 is the load-bearing precedent that a GI-targeted peptide can carry rigorous Phase 3 evidence to a marketed indication — not in inflammatory bowel disease, but in an adjacent intestinal-failure indication where the mucosal-growth mechanism aligns directly with the endpoint that regulators required.
The indication is short bowel syndrome with intestinal failure — adult patients with prior small-bowel resection on stable parenteral support — and is not a Crohn's-disease or ulcerative-colitis indication. Subgroup analyses showing teduglutide works comparably in patients whose SBS-IF etiology was Crohn's-related versus non-Crohn's-related are informative about the GLP-2-receptor pharmacology not being disrupted by underlying Crohn's biology, not evidence that teduglutide treats Crohn's. The 86-patient sample is small by modern Phase 3 standards but appropriate for an orphan-class intestinal-failure population in which the underlying disease prevalence constrains achievable enrollment. Industry sponsorship by NPS Pharmaceuticals (now part of Takeda) is disclosed; the regulatory dossier survived FDA and EMA review. The 24-week trial duration is short relative to the chronic-therapy framing the molecule now carries; longer-term efficacy and the GLP-2-class neoplasia-surveillance considerations (especially in patients with prior or active Crohn's, where small-bowel neoplasia baseline risk is elevated) are addressed in STEPS-2 and subsequent post-marketing surveillance. Teduglutide is administered by once-daily subcutaneous injection and remains expensive; the access and cost framings constrain real-world deployment in ways the trial does not address. For the practitioner-peptide-stack context — BPC-157, KPV, and the GLP-1 retrospective-cohort literature in IBD — this paper is the negative-control point of comparison: a peptide development program that ran the trials, produced the data, and reached the indication. The peptide-stack molecules surveyed in the IBD-and-peptides dossier have not.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.